MCID: VLV034
MIFTS: 49

Vulva Squamous Cell Carcinoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases, Skin diseases

Aliases & Classifications for Vulva Squamous Cell Carcinoma

MalaCards integrated aliases for Vulva Squamous Cell Carcinoma:

Name: Vulva Squamous Cell Carcinoma 12 15
Vulvar Squamous Cell Carcinoma 12 58 17
Squamous Cell Carcinoma of Vulva 12 70
Squamous Cell Carcinoma of the Vulva 58
Vulvar Epidermoid Carcinoma 12

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 12 DOID:2101
NCIt 50 C4052
SNOMED-CT 67 254895003
Orphanet 58 ORPHA494448
UMLS 70 C0280856

Summaries for Vulva Squamous Cell Carcinoma

Disease Ontology : 12 A vulva carcinoma and has material basis in squamous cells and is located in the epidermis of the vulvar tissue.

MalaCards based summary : Vulva Squamous Cell Carcinoma, also known as vulvar squamous cell carcinoma, is related to squamous cell papilloma and vulvar intraepithelial neoplasia. An important gene associated with Vulva Squamous Cell Carcinoma is MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1), and among its related pathways/superpathways are Regulation of TP53 Activity and Human cytomegalovirus infection. The drugs Cisplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include epidermis of the vulvar tissue, breast and lymph node, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Vulva Squamous Cell Carcinoma

Diseases related to Vulva Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 266)
# Related Disease Score Top Affiliating Genes
1 squamous cell papilloma 31.3 TP53 GP5 CDKN2A
2 vulvar intraepithelial neoplasia 30.9 TP53 CDKN2A
3 human papillomavirus infectious disease 30.7 TP53 CDKN2A
4 vaginal cancer 30.6 TP53 GP5 CDKN2A
5 suppressor of tumorigenicity 3 30.5 TP53 CDKN2A
6 keratosis 30.5 TP53 PIK3CA CDKN2A
7 cervix uteri carcinoma in situ 30.5 TP53 GP5 CDKN2A
8 vulvar dystrophy 30.5 ZNF652 TP53 CDKN2A
9 verrucous carcinoma 30.3 TP53 EGFR CDKN2A
10 keratinizing squamous cell carcinoma 30.3 TP53 EGFR CDKN2A
11 in situ carcinoma 30.2 TP53 PIK3CA EGFR CDKN2A
12 basaloid squamous cell carcinoma 30.0 TP53 EGFR CDKN2A
13 uterine corpus cancer 29.9 TP53 PIK3CA EGFR CDKN2A
14 cervical squamous cell carcinoma 29.8 TP53 PIK3CA EGFR CDKN2A
15 squamous cell carcinoma 29.6 TP53 PIK3CA MALAT1 EGFR CDKN2A
16 adenosquamous carcinoma 29.6 TP53 PIK3CA EGFR CDKN2A CD274
17 skin carcinoma 29.4 TP53 PIK3CA EGFR CDKN2A CD274
18 melanoma 29.3 TP53 PIK3CA MEG3 MALAT1 EGFR CDKN2A
19 vulvar disease 29.1 TP53 PIK3CA MIR3147 GP5 EGFR CDKN2A
20 vulva cancer 28.4 ZNF652 TP53 PLXDC2 PIK3CA MIR590 MIR3147
21 vulva verrucous carcinoma 11.3
22 vulvar basaloid squamous cell carcinoma 11.3
23 vulvar keratinizing squamous cell carcinoma 11.3
24 vulvar keratoacanthoma-like carcinoma 11.3
25 vulvar non-keratinizing squamous cell carcinoma 11.3
26 lichen sclerosus et atrophicus 10.8
27 papilloma 10.6
28 undifferentiated embryonal sarcoma of the liver 10.4 TP53 MALAT1
29 embryonal sarcoma 10.4 TP53 MALAT1
30 ovarian seromucinous carcinoma 10.4 TP53 CDKN2A
31 spitz nevus 10.4 TP53 CDKN2A
32 bizarre leiomyoma 10.3 TP53 CDKN2A
33 adult malignant schwannoma 10.3 TP53 CDKN2A
34 comedo carcinoma 10.3 TP53 GP5
35 epstein-barr virus-associated gastric carcinoma 10.3 CDKN2A CD274
36 primary cutaneous diffuse large b-cell lymphoma, leg type 10.3 CDKN2A CD274
37 localized osteosarcoma 10.3 TP53 CDKN2A
38 malignant exocrine pancreas neoplasm 10.3 TP53 CDKN2A
39 thyroid lymphoma 10.3 TP53 CDKN2A
40 bladder clear cell adenocarcinoma 10.3 TP53 CDKN2A
41 chronic cervicitis 10.3 TP53 GP5 CDKN2A
42 adenoid squamous cell carcinoma 10.3
43 uterus carcinoma in situ 10.3 TP53 GP5 CDKN2A
44 anogenital venereal wart 10.3 TP53 GP5 CDKN2A
45 parameningeal embryonal rhabdomyosarcoma 10.3 TP53 PIK3CA
46 ovarian epithelial cancer 10.2 PIK3CA MEG3 MALAT1
47 cervical adenosarcoma 10.2 TP53 GP5
48 malignant spiradenoma 10.2 TP53 PIK3CA CDKN2A
49 prostate squamous cell carcinoma 10.2 TP53 PIK3CA CDKN2A
50 acanthoma 10.2 TP53 PIK3CA CDKN2A

Graphical network of the top 20 diseases related to Vulva Squamous Cell Carcinoma:



Diseases related to Vulva Squamous Cell Carcinoma

Symptoms & Phenotypes for Vulva Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Vulva Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

26 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-105 9.6 SFN
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-113 9.6 SFN
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 9.6 PIK3CA
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-118 9.6 EGFR
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-157 9.6 PIK3CA
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-16 9.6 PIK3CA
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-166 9.6 PIK3CA
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 9.6 PIK3CA
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 9.6 SFN
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-190 9.6 EGFR PIK3CA SFN
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.6 PIK3CA
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-4 9.6 SFN
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-42 9.6 PIK3CA
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 9.6 PIK3CA
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.6 PIK3CA
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 9.6 SFN
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-58 9.6 EGFR

Drugs & Therapeutics for Vulva Squamous Cell Carcinoma

Drugs for Vulva Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 21)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
2
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
3
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
4
Pembrolizumab Approved Phase 2 1374853-91-4
5
Gemcitabine Approved Phase 2 95058-81-4 60750
6 Antimitotic Agents Phase 2
7 Albumin-Bound Paclitaxel Phase 2
8 Tubulin Modulators Phase 2
9 Antineoplastic Agents, Immunological Phase 2
10 Immunosuppressive Agents Phase 2
11 Antiviral Agents Phase 2
12 Anti-Infective Agents Phase 2
13 Antimetabolites Phase 2
14 Immunologic Factors Phase 2
15
Ethanol Approved 64-17-5 702
16
Dimenhydrinate Approved 523-87-5 441281
17
Hydrogen peroxide Approved, Vet_approved 7722-84-1 784
18 Pharmaceutical Solutions
19 Immunoglobulins
20 Antibodies
21 Anesthetics

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 Phase III Radiation Therapy vs Pelvic Node Resection for Previously Untreated Invasive Squamous Cell Carcinoma of the Vulva With Positive Groin Nodes Completed NCT00898352 Phase 3
2 Intraoperative Lymphatic Mapping in Patients With Stage I and II Squamous Carcinoma of the Vulva Completed NCT00003325 Phase 3
3 A Randomized Study of Adjuvant Radiation Treatment Versus Radiation and Chemotherapy in Patients With Vulvar Cancer and Involved Nodes Terminated NCT00006096 Phase 3 cisplatin
4 Phase II Clinical Trial On Taxol As Single Agent In Locally Advanced And/Or Metastatic Or Recurrent Vulva Cancer Not Amenable For Surgery And/Or Radiotherapy Completed NCT00014599 Phase 2 paclitaxel
5 A Phase II Trial of Radiation Therapy and Weekly Cisplatin Chemotherapy for the Treatment of Locally-Advanced Squamous Cell Carcinoma of the Vulva Completed NCT00068406 Phase 2 Cisplatin
6 Treatment of Metastatic Vulvar Carcinoma With Carboplatin and Paclitaxel Chemotherapy (CRAVAT) Recruiting NCT04161664 Phase 2 Paclitaxel and Carboplatin
7 Treatment of Locally Advanced VULvar CArcinoma in a Neoadjuvant Setting With Carboplatin and Paclitaxel Chemotherapy (VULCANize) Recruiting NCT04192253 Phase 2 Paclitaxel and Carboplatin
8 A Phase 2 Study of Combined Chemo-immunotherapy With Cisplatin-pembrolizumab and Radiation for Unresectable Vulvar Squamous Cell Carcinoma Recruiting NCT04430699 Phase 2 Cisplatin;Pembrolizumab
9 A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061) Active, not recruiting NCT01595061 Phase 2 Cisplatin;Gemcitabine Hydrochloride
10 Study of The Examination of Sentinel Lymph Nodes for OX-40 Expression in Patients With Cancer Completed NCT00900302
11 Indocyanine Green Fluorescence Imaging, Sentinel Lymph Node Mapping in Patients With Vulvar Cancer: Peritumoral Injection Dosage and Waiting Times in Our Experience Recruiting NCT04663412
12 A Safety and Efficacy Study of Intra-tumoural Diffusing Alpha Radiation Emitters (DaRT) for the Treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva Not yet recruiting NCT04761146

Search NIH Clinical Center for Vulva Squamous Cell Carcinoma

Genetic Tests for Vulva Squamous Cell Carcinoma

Anatomical Context for Vulva Squamous Cell Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Vulva Squamous Cell Carcinoma:

19
Epidermis Of The Vulvar Tissue

MalaCards organs/tissues related to Vulva Squamous Cell Carcinoma:

40
Breast, Lymph Node, Lung, Skin, Bone, Thyroid, Ovary

Publications for Vulva Squamous Cell Carcinoma

Articles related to Vulva Squamous Cell Carcinoma:

(show top 50) (show all 441)
# Title Authors PMID Year
1
Recurrence of vulvar squamous cell carcinoma as an undifferentiated sarcomatoid carcinoma. 61
33795407 2021
2
Four-decade trends in lymph node status of patients with vulvar squamous cell carcinoma in northern Italy. 61
33707570 2021
3
Perineural Invasion Correlates With Common Pathological Variables and Clinical Outcomes of Patients With Squamous Cell Carcinoma of the Vulva Treated With Primary Radical Surgery and Inguinal-femoral Lymphadenectomy. 61
33622901 2021
4
CXCR4/ACKR3/CXCL12 axis in the lymphatic metastasis of vulvar squamous cell carcinoma. 61
33692092 2021
5
[Vulvar intraepithelial neoplasias]. 61
33744030 2021
6
Patterns of recurrence and survival in vulvar cancer: A nationwide population-based study. 61
33736857 2021
7
The Immune Checkpoint Inhibitor LAG-3 and Its Ligand GAL-3 in Vulvar Squamous Neoplasia. 61
33782343 2021
8
Age, treatment and prognosis of patients with squamous cell vulvar cancer (VSCC) - analysis of the AGO-CaRE-1 study. 61
33648748 2021
9
Accuracy of computerized tomography in the preoperative evaluation of metastases in primary vulvar cancer - A population-based study. 61
33618843 2021
10
Molecular characterization of invasive and in situ squamous neoplasia of the vulva and implications for morphologic diagnosis and outcome. 61
32792599 2021
11
Comparison of p53 immunohistochemical staining in differentiated vulvar intraepithelial neoplasia (dVIN) with that in inflammatory dermatoses and benign squamous lesions in the vulva. 61
32799363 2021
12
Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial. 61
33574401 2021
13
The interaction of smoking habit, SLPI and AnxA2 in HPV associated head and neck and other cancers. 61
33387869 2021
14
p53 and p16 expression profiles in vulvar cancer: a translational analysis by the Arbeitsgemeinschaft Gynäkologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study group. 61
33453182 2021
15
Putative precancerous lesions of vulvar squamous cell carcinoma. 61
32948383 2021
16
A review of prognostic factors in squamous cell carcinoma of the vulva: Evidence from the last decade. 61
33246713 2021
17
Diagnostic Criteria for Differentiated Vulvar Intraepithelial Neoplasia and Vulvar Aberrant Maturation. 61
33105449 2021
18
Exosomal lncRNA UCA1 from cancer-associated fibroblasts enhances chemoresistance in vulvar squamous cell carcinoma cells. 61
32812305 2021
19
Radiotherapy is not indicated in patients with vulvar squamous cell carcinoma and only one occult intracapsular groin node metastasis. 61
33067000 2021
20
Molecular events in the pathogenesis of vulvar squamous cell carcinoma. 61
33032902 2021
21
Vulvar intraepithelial neoplasia: Incidence and long-term risk of vulvar squamous cell carcinoma. 61
32638382 2021
22
Erosive Vulvar Lichen Planus and Risk of Vulvar Neoplasia. 61
33214502 2021
23
DNA methylation markers for cancer risk prediction of vulvar intraepithelial neoplasia. 61
33426639 2021
24
Reconstruction of a radical total vulvectomy defect with a single split anterolateral thigh perforator flap: A case report and review of the literature. 61
32339351 2021
25
Utilization and outcomes of sentinel lymph node biopsy in patients with early stage vulvar cancer. 61
33243778 2021
26
Near-infrared fluorescence imaging compared to standard sentinel lymph node detection with blue dye in patients with vulvar cancer - a randomized controlled trial. 61
33041071 2020
27
Low incidence of pulmonary metastases in vulvar cancer patients: limited value of routine chest imaging based on a cohort study. 61
33342026 2020
28
Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes. 61
32972785 2020
29
Reducing the radicality of surgery for vulvar cancer: are smaller margins safe? 61
33306289 2020
30
Primary treatment and relative survival by stage and age in vulvar squamous cell carcinoma: A population-based SweGCG study. 61
32988623 2020
31
Inflammatory Proteins HMGA2 and PRTN3 as Drivers of Vulvar Squamous Cell Carcinoma Progression. 61
33374674 2020
32
A prognostic nomogram based on lymph node ratio for postoperative vulvar squamous cell carcinoma from the Surveillance, Epidemiology, and End Results database: a retrospective cohort study. 61
33313127 2020
33
Common Benign Chronic Vulvar Disorders. 61
33118795 2020
34
HPV-independent Precursors Mimicking High-grade Squamous Intraepithelial Lesions (HSIL) of the Vulva. 61
32657782 2020
35
[Prognostic significance of groin lymph node ratio in vulvar squamous cell carcinoma]. 61
32339764 2020
36
A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma. 61
32928237 2020
37
Tumor-free margins and local recurrence in squamous cell carcinoma of the vulva. 61
32624236 2020
38
A review of prognostic factors in squamous cell carcinoma of the vulva: Evidence from the last decade. 61
32988675 2020
39
Genomic characterization of vulvar squamous cell carcinoma. 61
32591094 2020
40
Practical Guidance for Measuring and Reporting Surgical Margins in Vulvar Cancer. 61
31460873 2020
41
Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status. 61
32203095 2020
42
Genes, pathways and vulvar carcinoma - New insights from next-generation sequencing studies. 61
32522421 2020
43
Somatic Mutation Profiling in Premalignant Lesions of Vulvar Squamous Cell Carcinoma. 61
32664330 2020
44
Association of Topical Corticosteroids With Reduced Vulvar Squamous Cell Carcinoma Recurrence in Patients With Vulvar Lichen Sclerosus. 61
32374363 2020
45
Predictive Value of an Alternative Strategy for Measuring Depth and Size of Stage 1 Vulvar Squamous Cell Carcinoma. 61
32366757 2020
46
HPV-independent Vulvar Squamous Cell Carcinoma is Associated With Significantly Worse Prognosis Compared With HPV-associated Tumors. 61
31274700 2020
47
Performance of the pattern-based interpretation of p53 immunohistochemistry as a surrogate for TP53 mutations in vulvar squamous cell carcinoma. 61
32236967 2020
48
Molecular pathways in vulvar squamous cell carcinoma: implications for target therapeutic strategies. 61
32335720 2020
49
Immune checkpoint status and tumor microenvironment in vulvar squamous cell carcinoma. 61
31993774 2020
50
Incidence trends of vulvar squamous cell carcinoma in Italy from 1990 to 2015. 61
32273199 2020

Variations for Vulva Squamous Cell Carcinoma

Cosmic variations for Vulva Squamous Cell Carcinoma:

9 (show top 50) (show all 1309)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM122736660 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.59C>T p.P20L 17:7675157-7675157 12
2 COSM93191413 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.482C>T p.A161V 17:7675130-7675130 12
3 COSM87899887 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.856G>A p.E286K 17:7673764-7673764 12
4 COSM142560375 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.736G>A p.E246K 17:7673767-7673767 12
5 COSM105620380 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.782+414G>A p.? 17:7673767-7673767 12
6 COSM144013457 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.820G>A p.E274K 17:7673767-7673767 12
7 COSM144013161 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.557T>G p.V186G 17:7674941-7674941 12
8 COSM144290515 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.637G>C p.E213Q 17:7674861-7674861 12
9 COSM112255951 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.455C>T p.P152L 17:7675157-7675157 12
10 COSM144309944 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.407G>A p.R136H 17:7675088-7675088 12
11 COSM111878732 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.775G>C p.D259H 17:7674188-7674188 12
12 COSM122738565 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.250G>A p.V84M 17:7674885-7674885 12
13 COSM122735959 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.*43C>T p.? 17:7670685-7670685 12
14 COSM93183307 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.524G>A p.R175H 17:7675088-7675088 12
15 COSM144087106 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.266G>A p.R89Q 17:7674220-7674220 12
16 COSM145020119 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.497A>G p.Y166C 17:7674917-7674917 12
17 COSM105620358 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.451C>T p.P151S 17:7675161-7675161 12
18 COSM144013367 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.710G>A p.R237Q 17:7674220-7674220 12
19 COSM112309251 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.339C>G p.F113L 17:7676030-7676030 12
20 COSM143157028 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.340C>T p.R114C 17:7673803-7673803 12
21 COSM144366627 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.415C>T p.H139Y 17:7675080-7675080 12
22 COSM143389578 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.397G>A p.V133I 17:7675098-7675098 12
23 COSM111758876 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.844C>T p.R282W 17:7673776-7673776 12
24 COSM111761580 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.455C>T p.P152L 17:7675157-7675157 12
25 COSM142837563 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.817C>T p.R273C 17:7673803-7673803 12
26 COSM122734046 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.263A>G p.Y88C 17:7674872-7674872 12
27 COSM122792873 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.306C>A p.Y102* 17:7674261-7674261 12
28 COSM87898723 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.817C>T p.R273C 17:7673803-7673803 12
29 COSM87898424 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.722C>T p.S241F 17:7674241-7674241 12
30 COSM142561357 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.452C>T p.P151L 17:7674962-7674962 12
31 COSM145019215 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.739G>A p.E247K 17:7673764-7673764 12
32 COSM143943797 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.266G>A p.R89Q 17:7674220-7674220 12
33 COSM122271635 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.55C>T p.P19S 17:7675161-7675161 12
34 COSM143156843 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.266G>A p.R89Q 17:7674220-7674220 12
35 COSM144311333 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.726C>G p.D242E 17:7673777-7673777 12
36 COSM143409179 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.876+1G>C p.? 17:7673534-7673534 12
37 COSM122734486 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.520C>T p.R174* 17:7673704-7673704 12
38 COSM93239606 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.702C>A p.Y234* 17:7674261-7674261 12
39 COSM106053265 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.853G>A p.E285K 17:7673767-7673767 12
40 COSM106053452 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.817C>T p.R273C 17:7673803-7673803 12
41 COSM144016191 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.422C>T p.P141L 17:7675157-7675157 12
42 COSM112292789 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.993+1G>C p.? 17:7673534-7673534 12
43 COSM112578970 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.670G>C p.E224Q 17:7674861-7674861 12
44 COSM122288931 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.132C>A p.C44* 17:7675084-7675084 12
45 COSM144345858 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.751C>T p.R251C 17:7673752-7673752 12
46 COSM144310279 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.736G>A p.E246K 17:7673767-7673767 12
47 COSM143370575 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.701G>A p.R234H 17:7673802-7673802 12
48 COSM111758637 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.451C>T p.P151S 17:7675161-7675161 12
49 COSM142837558 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.844C>T p.R282W 17:7673776-7673776 12
50 COSM93229231 TP53 vulva,NS,carcinoma,squamous cell carcinoma c.868C>T p.R290C 17:7673752-7673752 12

Expression for Vulva Squamous Cell Carcinoma

Search GEO for disease gene expression data for Vulva Squamous Cell Carcinoma.

Pathways for Vulva Squamous Cell Carcinoma

Pathways related to Vulva Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.85 YWHAH TP53 SFN CDKN2A CDC25C
2
Show member pathways
12.73 WEE1 TP53 PIK3CA EGFR CDKN2A CDC25C
3
Show member pathways
12.56 YWHAH TP53 SFN PIK3CA CDKN2A
4
Show member pathways
12.46 YWHAH SFN PIK3CA EGFR
5
Show member pathways
12.46 YWHAH WEE1 TP53 SFN CDC25C
6
Show member pathways
12.33 YWHAH TP53 PIK3CA EGFR
7 12.29 TP53 PIK3CA EGFR CDKN2A CDC25C
8
Show member pathways
12.26 TP53 SFN CDKN2A CDC25C
9 12.21 YWHAH WEE1 TP53 SFN CDKN2A CDC25C
10 12.16 YWHAH TP53 PIK3CA CDKN2A
11
Show member pathways
12.02 YWHAH WEE1 TP53 PIK3CA EGFR
12 11.99 YWHAH WEE1 TP53 SFN CDKN2A CDC25C
13 11.87 TP53 PIK3CA CDKN2A
14 11.85 TP53 EGFR CDKN2A
15
Show member pathways
11.81 TP53 SFN CDC25C
16 11.72 YWHAH TP53 SFN
17 11.69 YWHAH TP53 SFN
18 11.67 YWHAH TP53 SFN
19 11.63 YWHAH SFN PIK3CA EGFR
20 11.62 TP53 PIK3CA CDKN2A
21 11.61 TP53 EGFR CDKN2A
22 11.58 TP53 PIK3CA EGFR
23 11.41 TP53 EGFR CDKN2A
24 11.28 YWHAH TP53 SFN
25 11.05 YWHAH SFN PIK3CA
26 10.75 YWHAH SFN PIK3CA EGFR
27 10.7 TP53 MEG3
28
Show member pathways
10.67 YWHAH WEE1 TP53 SFN CDC25C
29 10.21 TP53 CDC25C

GO Terms for Vulva Squamous Cell Carcinoma

Biological processes related to Vulva Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.43 TP53 SFN CDC25C
2 replicative senescence GO:0090399 9.37 TP53 CDKN2A
3 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.32 TP53 EGFR
4 negative regulation of cell growth GO:0030308 9.26 TP53 NAIF1 MEG3 CDKN2A
5 regulation of mitochondrial membrane permeability involved in apoptotic process GO:1902108 9.16 TP53 NAIF1
6 positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:1900740 8.8 YWHAH TP53 SFN

Molecular functions related to Vulva Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.02 TP53 SFN EGFR CDKN2A CDC25C
2 MDM2/MDM4 family protein binding GO:0097371 8.96 TP53 CDKN2A

Sources for Vulva Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....